Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.

Gabriel BstehHamid AssarChristiane GradlBettina HeschlMaria-Sophie HillerNik KrajncFranziska Di Pauli Harald HegenGerhard TraxlerFritz LeutmezerPeter WipflerGudrun ZulehnerMichael GugerChristian EnzingerThomas Bergernull null

Published in: European journal of neurology (2022)

Long-term outcome of COVID-19 is favourable in a large majority of pwMS with only a small proportion of patients suffering from persistent symptoms usually resolving after 3-6 months. COVID-19 is not associated with increased risk of relapse or disability.

Keyphrases

multiple sclerosis
coronavirus disease
sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
depressive symptoms